If you are an Aetna member and received a letter regarding contract negotiations with NewYork-Presbyterian, you may find out the latest information here.

Joseph Michael Scandura, M.D., Ph.D.

Medical Oncology

Locations and Appointments

Insurances Accepted

Please contact the doctor's office to verify that your insurance is accepted.

  • HMO
  • Medicare
  • PPO
  • EPO/POS
  • CHP
  • Blue Access
  • Blue Connection
  • EPO
  • HMO
  • Mediblue (Senior)
  • PPO
  • CBP
  • Medicaid
  • Medicare
  • Freedom
  • Liberty
  • Medicare Advantage
  • Metro/Core/Charter
  • Community Plan
  • Medicare
  • HMO
  • Medicare
Personal Statement

I am a physician-scientist working clinically and in the laboratory to develop curative treatment strategies for blood cancers.

Biographical Info

Dr. Scandura received a B.S. in Electrical Engineering from Cornell Ithaca in 1987, and an MS in Biomedical Engineering at the University of Pennsylvania in 1992. He completed the MD/PhD program in Biochemistry at Temple University in 1997. His doctoral work investigating critical interactions between platelets and coagulation factors led to three first-authored papers in Biochemistry.

Following his residency in internal medicine-research track at Weill Medical College, New York Presbyterian Hospital from 1997-1999, Dr. Scandura did a Fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center from 1999-2003. Dr. Scandura was appointed Instructor on the Leukemia Service at Memorial in 2003, and an Instructor in Clinical Medicine at Weill Medical College in 2004. He served as an inpatient attending on the Memorial Leukemia Service and outpatient Leukemia Clinic.

In 2006, Dr. Scandura joined the Division of Hematology and Medical Oncology at Weill/Cornell to serve in the Leukemia Program. He is Assistant Professor of Medicine at Weill Cornell Medical College, and Assistant Attending Physician at the NewYork-Presbyterian Hospital. Dr. Scandura contributes as attending physician on the inpatient clinical services for the Division and as covering physician for the Hematology/Oncology inpatients. He also maintains an ambulatory clinic in the Leukemia and Myclodysplastic Syndromes Program in the outpatient department of the Division. Working collaboratively with other faculty members of the Division of Hematology and Medical Oncology, he is helping to develop both sponsored research activities and the Leukemia Program.

Honors and Awards
1984-1987 Red Key Athletic Honor Society, Cornell University
1985-1987 Sphinx Head Society, Cornell University
1986-1987 Dean's List, Cornell University
1992 Young Investigator Award, American Heart Association
1993 Young Investigator Award, American Society of Hematology
1995 Travel Grant Award, International Society for Thrombosis and Haemostasis
1996 Alpha Omega Alpha Honor Medical Society, Epsilon Chapter
2002 Charles A. Dana Fellow, Memorial Sloan-Kettering Cancer Center
2002 Leukemia & Lymphoma Society, Fellow Award
Board Certifications
American Board of Internal Medicine
American Board of Internal Medicine (Medical Oncology)
Clinical Expertise
Molecular Medicine
Leukemia
Acute Myelogenous Leukemia
Myeloproliferative Disorder
Myelodysplastic Syndrome
Polycythemia Vera
Essential Thrombocythemia
Myelofibrosis
Hematopoietic Disorder
MPN (Myeloproliferative Neoplasm)
Languages
English
Education 
  • M.D., Ph.D.
    Temple University School of Medicine
    1997
  • M.S.
    University of Pennsylvania
    1992
Appointments 
  • Associate Attending Physician
    NewYork-Presbyterian Hospital
  • Associate Professor of Medicine
    Weill Cornell Medical College, Cornell University
Videos

About Us | Richard T. Silver Myeloproliferative Neoplasms (MPN) Center

Relationships and collaborations with for-profit and not-for profit organizations are of vital importance to our faculty because these exchanges of scientific information foster innovation. As experts in their fields, WCM physicians and scientists are sought after by many organizations to consult and educate. WCM and its faculty make this information available to the public, thus creating a transparent environment.

Consultant: 
Sumitomo Dainippon Pharma Oncology, Inc
Advisory/Scientific Board Member: 
GlaxoSmithKline
Karyopharm Therapeutics, Inc.